✦ LIBER ✦

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

✍ Scribed by T. Forst; B. Uhlig-Laske; A. Ring; U. Graefe-Mody; C. Friedrich; K. Herbach; H.-J. Woerle; K. A. Dugi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and Tolerability of the DPP-4 I

✍ DeFronzo, R. A.; Burant, C. F.; Fleck, P.; Wilson, C.; Mekki, Q.; Pratley, R. E. 📂 Article 📅 2012 🏛 Endocrine Society 🌐 English ⚖ 427 KB

Efficacy and safety of linagliptin in pe

✍ D. R. Owens; R. Swallow; K. A. Dugi; H. J. Woerle 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Serum level of soluble CD26/dipeptidyl p

✍ Yoshimasa Aso; Noriyuki Ozeki; Tomoko Terasawa; Rika Naruse; Kenji Hara; Mariko 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 210 KB

Efficacy and Safety of the Dipeptidyl Pe

✍ Charbonnel, B.; Karasik, A.; Liu, J.; Wu, M.; Meininger, G. 📂 Article 📅 2006 🏛 American Diabetes Association 🌐 English ⚖ 148 KB

Efficacy and safety of initial combinati

✍ R. Gomis; R.-M. Espadero; R. Jones; H. J. Woerle; K. A. Dugi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 849 KB

2-year efficacy and safety of linaglipti

✍ Baptist Gallwitz; Julio Rosenstock; Thomas Rauch; Sudipta Bhattacharya; Sanjay P 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 289 KB